Article

Notal Vision sells Foresee PHP business to Reichert

Notal Vision has sold its clinic-based preferential hyperacuity perimeter (Foresee PHP) business to Reichert Ophthalmic Instruments.

Minneapolis

-Notal Vision has sold its clinic-based preferential hyperacuity perimeter (Foresee PHP) business to Reichert Ophthalmic Instruments.

Notal Vision sold the professional visual field analyzer, according to the company, so that it could fully invest its time and resources in its home-based PHP device, which the company previewed at the recent annual meeting of the American Academy of Ophthalmology and expects to launch in 2010. Sightpath Medical, previous distributor of the clinic-based PHP instrument, will distribute the home-based PHP device.

“Sightpath Medical and Reichert are working together to ensure a smooth transition for our [professional] PHP customers,” said Jim Tiffany, president and chief operating officer of TLCVision Corp. and its Sightpath Medical subsidiary. Reichert will assume responsibility as the warranty and service provider for all new clinic-based customers immediately and will begin servicing pre-existing customers Nov. 16.

Notal Vision invented the PHP technology in 2001 to assist in monitoring patients for the conversion from dry to wet age-related macular degeneration (AMD). The technology is the basis of both the clinic-based PHP and the home-based PHP, which will aim to help patients with AMD monitor the condition daily in their homes.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.